Skip to main content

Table 3 Non-hematological toxicity

From: Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life

 

All Grades (%)

Grade 3 (%)

Grade 4 (%)

Astenia/fatigue

49 (43.4)

5 (4.4)

Peripheral neuropathy

14 (12.4)

1 (0.9)

Arthralgia/myalgia

9 (7.9)

Hypertransaminasemia

8 (7.1)

1 (0.9)

Abnormal liver function test

18 (15.9)

2 (1.8)

Stomatitis

5 (4.4)

1 (0.9)

Nausea/vomiting

9 (7.9)

Alopecia

19 (16.8)

Diarrhea

6 (5.3)

Constipation

3 (2.6)

Cough

2 (1.8)

Dyspnea

4 (3.5)

1 (1.09)